Skip to main content

Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report

Journal of Neurology volume 262, pages 219–221 (2015)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Miravalle A, Jensen R, Kinkel P (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68(2):186–191

    Article  PubMed  Google Scholar 

  2. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J et al (2012) Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71(7):604–617

    CAS  Article  PubMed  Google Scholar 

  3. Tan IL, McArthur JC, Clifford DB et al (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77(11):1061–1067

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  4. Clifford DB, DeLuca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446

    CAS  Article  PubMed  Google Scholar 

  5. Salhofer-Polanyi S, Baumgartner A, Kraus J et al (2014) What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand 130(2):97–102

    CAS  Article  PubMed  Google Scholar 

  6. Lenhard T, Biller A, Mueller W et al (2010) Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 75(9):831–833

    CAS  Article  PubMed  Google Scholar 

  7. Daelman L, Maitrot A, Maarouf A et al (2012) Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 18(11):1647–1649

    CAS  Article  PubMed  Google Scholar 

  8. Rigau V, Mania A, Béfort P et al (2012) Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 79(22):2214–2216

    Article  PubMed  Google Scholar 

  9. Vennegoor A, Wattjes MP, van Munster ET et al (2011) Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 76(6):574–576

    CAS  Article  PubMed  Google Scholar 

  10. Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  11. Borriello G, Prosperini L, Mancinelli C et al (2012) Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 19:783–787

    CAS  Article  PubMed  Google Scholar 

  12. Capobianco M, di Sapio A, Malentacchi M et al (2014) No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol. doi:10.1111/ene.12487

  13. Havla J, Gerdes LA, Meinl I et al (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665–1669

    CAS  Article  PubMed  Google Scholar 

  14. Havla J, Tackenberg B, Hellwig K et al (2013) Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 260:1382–1387

    CAS  Article  PubMed  Google Scholar 

  15. Jokubaitis VG, Li V, Kalincik T et al (2014) Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82:1204–1211

    PubMed Central  CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This case report received no specific grant from any funding agency.

Conflicts of interest

Maria Sepúlveda, Sara Llufriu, Yolanda Blanco, Núria Solà-Valls, Delon La Puma and Joan Berenguer report no disclosures. Pablo Villoslada reports having received consultancy fees in the last year from Roche, Novartis and Bionure Incorporation. Albert Saiz has received compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd. and Novartis.

Ethical standards

All patients and controls provided written informed consent and the local ethics committee approved the study which has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Author information

Affiliations

  1. Center for Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain

    Maria Sepúlveda, Sara Llufriu, Yolanda Blanco, Nuria Solà-Valls, Delon La Puma, Pablo Villoslada & Albert Saiz

  2. Service of Radiology and Imaging Diagnostic Center, Radiology Department, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain

    Joan Berenguer

Authors
  1. Maria Sepúlveda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Llufriu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yolanda Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nuria Solà-Valls
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Delon La Puma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joan Berenguer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pablo Villoslada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Albert Saiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Saiz.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sepúlveda, M., Llufriu, S., Blanco, Y. et al. Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. J Neurol 262, 219–221 (2015). https://doi.org/10.1007/s00415-014-7574-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-014-7574-6

Keywords

  • Expand Disability Status Scale
  • Progressive Multifocal Leukoencephalopathy
  • Natalizumab
  • Glatiramer Acetate
  • Fingolimod